Investor Presentaiton slide image

Investor Presentaiton

R&D investor presentation Once-weekly insulin icodec appeared to have a similar safety profile to once-daily insulin glargine U100 in the phase 2 trial No statistically significant difference in the number of hypoglycaemic events between icodec and glargine U100 11 Insulin icodec appeared to have a safe profile Hyoglycemia during Icodec Glargine U100 Rates of nocturnal events were low the on-treatment N E E period (%) (R) (%) (R) Hypoglycaemia alert 67 368 46 value (Level 1) (53.6) (508.89) (37.7) 148 (210.80) No cardiovascular events Severe (Level 3) or 20 clinically significant (16.0) 38 (52.55) 12 (9.8) 32 No new safety issues identified related to insulin icodec (45.58) (Level 2) hypoglycaemia Severe hypoglycaemia (Level 3) 1 1 0 (0.8) (1.38) N: number of patients with one or or more events; E: number of events; %: percentage of patients with one or more events; R: rate (number of events divided by patient years of exposure multiplied by 100) novo nordisk
View entire presentation